Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022.

Net income was $69.4 million, or $1.04 per diluted share, compared to $1.6 million, or $0.03 per diluted share, for Q1 2022.

As of March 31, 2023, cash and cash equivalents were $1.2 billion, and the outstanding principal balance of the company's long-term debt was $5.8 billion. In addition, the company had undrawn borrowing capacity under a revolving credit facility of $500 …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.